Back to search results

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Abroad (travel likely)RecruitingPHASE1

Conditions

Acute Myeloid Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Lucile Packard Children's Hospital /ID# 276015, Palo Alto, California, United States

  • New York Medical College /ID# 275597, Valhalla, New York, United States

  • Tristar Centennial Medical Center /ID# 275831, Nashville, Tennessee, United States

  • Perth Children'S Hospital /ID# 275673, Perth, Western Australia, Australia

  • Ospedale Pediatrico Bambino Gesù /ID# 275692, Rome, Roma, Italy

  • Seoul National University Hospital /ID# 276978, Seoul, Seoul Teugbyeolsi, South Korea

  • Samsung Medical Center /ID# 276979, Seoul, Seoul Teugbyeolsi, South Korea

  • National Taiwan University Hospital /ID# 276635, Taipei, Taiwan

Study leads

  • ABBVIE INC.

    Study Director

    AbbVie

View source on ClinicalTrials.gov(opens in a new tab)